Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, Japan, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. The company also provides the NeuroStrip, a wearable, miniaturized electromyography device; NeuroNode, a wireless, wearable sensor that allows users to access technology through bioelectric signals and spatial movements; and Cosmos Connect, a small portable control device that turns a single NeuroNode sensor into multiple outputs. In addition, it offers mounting systems under the Rehadapt brand, including wheelchair mounts, floor stands, and table stands; and switch systems comprising proximity, press, and finger switches. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is headquartered in Cremorne, Australia.
Price analytics
Returns
1 day
-1.6%
1 week
7.0%
1 month
-1.6%
3 months
-18.7%
6 months
1.7%
1 year
84.8%
3 years
-3.4%
Risk
Volatility (1y ann.)
106.9%
Beta vs ASX 200
0.18
Sharpe (1y)
1.00
VaR 95% (1-day)
-6.7%
Max drawdown (1y)
-39.8%
Off 1-year high
-34.4%
Technicals
RSI(14)
50
vs 50DMA
-0.7%
vs 200DMA
-4.3%
Trend
Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value79.0
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
55
Price / Sales
33
Growth12.4
Revenue growth (1y)
12
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health74.9
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
—
Current ratio
44
Debt / Equity
100
Quality (Profitability & Cash Flow)0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income—
No meaningful dividend — pillar excluded from the overall score.
Momentum45.2
6-month return vs ASX 200
52
Price vs 200-day average
36
Price vs 50-day average
47
Position in 52-week range
46
Hover a row's info icon for the exact rule. Bounds and weights are configurable in
the Django admin (Scoring configuration).